|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival显示文摘Objective: To elucidate the role and prognostic significance of lymphocyte activation-gene-3(LAG-3) in soft tissue sarcoma(STS).Methods: The expression of LAG-3 in patient and matched normal blood samples was analyzed by flow cytometry. The localization and prognostic values of LAG-3^+ cells in 163 STS patients were analyzed by immunohistochemistry. In addition, the expression of tumor-infiltrating CD3^+ T, CD4^+ T, and CD8^+ T cells and their role in the prognosis of STS were evaluated by immunohistochemistry. The effect of LAG-3 blockade was evaluated in an immunocompetent MCA205 fibrosarcoma mouse model.Results: Peripheral CD8^+ and CD4^+ T cells from STS patients expressed higher levels of LAG-3 than those from healthy donors.LAG-3 expression in STS was significantly associated with a poor clinical outcome(P = 0.038) and was correlated with high pathological grade(P < 0.001), advanced tumor stage(P = 0.016). Additionally, LAG-3 expression was highly correlated with CD8^+ T-cell infiltration(r = 0.7034, P < 0.001). LAG-3 was expressed in murine tumor-infiltrating lymphocytes, and its blockade decreased tumor growth and enhanced secretion of interferon-gamma by CD8^+ and CD4^+ T cells.Conclusions: LAG-3 blockade may be a promising strategy to improve the effects of targeted therapy in STS. | Yi Que Zhixin Fang Yuanxiang Guan Wei Xiao Bushu Xu Jingjing Zhao Huoying Chen Xinke Zhang Musheng Zeng Yao Liang Xing Zhang | 2019 | Cancer Biology & Medicine2019，16，2： | 9 |
| 2 | Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study显示文摘Background:Famitinib is a tyrosine kinase inhibitor against multiple targets,including vascular endothelial growth factor receptor 2/3,platelet-derived growth factor receptor,and stem cell factor receptor(c-kit).Previous studies have demonstrated anti-tumour activities of famitinib against a wide variety of advanced-stage solid cancers.We aimed to determine the safety and efficacy of famitinib with concurrent chemoradiotherapy(CCRT)in patients with locoregionally advanced nasopharyngeal carcinoma(NPC).We also evaluated the feasibility of contrast-enhanced ultrasound(D-CEUS)as a predictor of early tumour response to famitinib and to correlate functional parameters with clinical efficacy.Methods:The trial was conducted in subjects with stage III or IVa-b NPC using a 3+3 design of escalating fami-tinib doses.Briefly,subjects received 2 weeks of famitinib monotherapy followed by 7 weeks of famitinib plus CCRT.D-CEUS of the neck lymph nodes was performed at day 0,8 and 15 after famitinib was administered before starting concurrent chemoradiotherapy.End points included safety,tolerability and anti-tumour activity.Results:Twenty patients were enrolled(six each for 12.5,16.5 and 20 mg and two for 25 mg).Two patients in the 25 mg cohort developed dose-limiting toxicities,including grade 4 thrombocytopenia and grade 3 hypertension.The most common grade 3/4 adverse events were leukopenia,neutropenia and radiation mucositis.D-CEUS tests showed that more than 60%of patients achieved a perfusion parameter response after 2 weeks taking famitinib alone,and the parameter response was associated with disease improvement.In the famitinib monotherapy stage,three patients(15%)showed partial responses.The complete response rate was 65%at the completion of treatment and 95%3 months after the treatment ended.After a median follow-up of 44 months,the 3-year progression-free survival(PFS)and distant metastasis-free survival were 70%and 75%,respectively.Subjects with a decrease of perfusion parameter response,such as peak intensity decreased at least 30%after 1 week of famitinib treatment,had higher 3-year PFS(90.9%vs.44.4%,95%CI 73.7%-100%vs.11.9%-76.9%,P<0.001)than those with an increase or a reduction of less than 30%.Conclusions:The recommended famitinib dose for phase II trial is 20 mg with CCRT for patients with local advanced NPC.D-CEUS is a reliable and early measure of efficacy for famitinib therapies.Further investigation is required to confirm the effects of famitinib plus chemoradiotherapy. | Qiuyan Chen Linquan Tang Na Liu Feng Han Ling Guo Shanshan Guo Jianwei Wang Huai Liu Yanfang Ye Lu Zhang Liting Liu Pan Wang Yingqin Li Qingmei He Xiaoqun Yang Qingnan Tang Yang Li YuJing Liang XueSong Sun Chuanmiao Xie Yunxian Mo Ying Guo Rui Sun Haoyuan Mo Kajia Cao Xiang Guo Musheng Zeng Haiqiang Mai Jun Ma | 2018 | Cancer Communications2018，38，1： | 6 |
| 3 | In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures显示文摘 | Chao Ni Yuhui Chen Musheng Zeng Rongjuan Pei Yong Du Linquan Tang Mengyi Wang Yazhuo Hu Hanyu Zhu Meifang He Xiawei Wei Shan Wang Xiangkai Ning Manna Wang Jufang Wang Li Ma Xinwen Chen Qiang Sun Hong Tang Ying Wang Xiaoning Wang | 2015 | Cell Research2015，25，7： | 3 |
| 4 | Oncoprotein Bmi-1 Renders Apoptotic Resistance to Glioma Cells through Activation of the IKK-Nuclear Factor-κB Pathway显示文摘 | Jun Li Li-Yun Gong Li-Bing Song Li-Li Jiang Li-Ping Liu Jueheng Wu Jie Yuan Jun-Chao Cai Mian He Lan Wang Musheng Zeng Shi-Yuan Cheng Mengfeng Li | 2010 | The American Journal of Pathology2010，，2： | 1 |
| 5 | Bmi-1,a Polycomb Group Protein,Plays an Essential Role in Tumorigenesis and Metastasis显示文摘Dysregulation of polycomb group protein Bmi-1 expression has been linked with an invasive phenotype of certain human cancers and poor prognosis of patients; however, the underlying mechanisms are | Libing SONG Jun LI Wenting LIAO Yan FENG Wanli LIU Yixin ZENG Musheng ZENG | 2009 | 中国肺癌杂志2009，12，6： | 0 |
| 6 | High frequency of alternative splicing variants of the oncogene Focal Adhesion Kinase in neuroendocrine tumors of the pancreas and breast显示文摘The characteristic genetic abnormality of neuroendocrine neoplasms(NENs),a heterogeneous group of tumors found in various organs,remains to be identified.Here,based on the analysis of the splicing variants of an oncogene Focal Adhesion Kinase(FAK)in The Cancer Genome Atlas datasets that contain 9193 patients of 33 cancer subtypes,we found that Box 6/Box 7-containing FAK variants(FAK^(6/7))were observed in 7(87.5%)of 8 pancreatic neuroendocrine carcinomas and 20(11.76%)of 170 pancreatic ductal adenocarcinomas(PDACs).We tested FAK variants in 157 tumor samples collected from Chinese patients with pancreatic tumors,and found that FAK^(6/7)was positive in 34(75.6%)of 45 pancreatic NENs,19(47.5%)of 40 pancreatic solid pseudopapillary neoplasms,and 2(2.9%)of 69 PDACs.We further tested FAK splicing variants in breast neuroendocrine carcinoma(BrNECs),and found that FAK^(6/7)was positive in 14(93.3%)of 15 BrNECs but 0 in 23 non-NEC breast cancers.We explored the underlying mechanisms and found that a splicing factor serine/arginine repetitive matrix protein 4(SRRM4)was overexpressed in FAK^(6/7)-positive pancreatic tumors and breast tumors,which promoted the formation of FAK^(6/7)in cells.These results suggested that FAK^(6/7)could be a biomarker of NENs and represent a potential therapeutic target for these orphan diseases. | Dawei Xie Zheng Wang Beibei Sun Liwei Qu Musheng Zeng Lin Feng Mingzhou Guo Guizhen Wang Jihui Hao Guangbiao Zhou | 2023 | Frontiers of Medicine2023，17，5： | 0 |
| 7 | 细胞浆中与NF-KB相互作用的长非编码RNA NKILA通过调控IkB磷酸化抑制乳腺癌转移显示文摘细胞出版社《癌细胞》杂志创刊于2002年,其旨在出版具有高影响力的癌症研究论文。《癌细胞》每年出版12期,每期正式出版前会选择部分文章提前在线出版。该杂志2015年公布的影响因子为23.523。 | Bodu Liu Lijuan Sun Qiang Liu Chang Gong Yandan Yao Xiaobin Lv Ling Lin Herui Yao Fengxi Su Dangsheng Li Musheng Zeng 宋尔卫 | 2016 | 科学新闻2016，0，1： | 0 |
| 8 | First-in-human pilot study of an integrinα6-targeted radiotracer for SPECT imaging of breast cancer显示文摘Dear Editor,The molecular classification has been playing a crucial role in the precise theranostics of cancer.Compared with the invasive biopsy,the in vivo noninvasive detection of biomarkers by nuclear imaging possesses advantages due to tumor heterogeneity.As one member of the integrin family,integrinα6 subunit combines the integrinβ1 orβ4 subunit to form integrinα6β1 orα6β4 heterodimers,which function to promote the migration,invasion,and survival of tumor cells,leading to increased metastasis,poor prognosis,and reduced survival.Therefore,the in vivo imaging of integrinα6 expression could play an important role in the treatment planning and prognosis prediction. | Shi Gao Bing Jia Guokai Feng Chengyan Dong Hui Du Lin Bai Qian Zhong Qingjie Ma Musheng Zeng Fan Wang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 0 |
| 9 | Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response显示文摘Epstein-Barr virus(EBV)and human papillomavirus(HPV)infection is the risk factors for nasopharyngeal carcinoma and cervical carcinoma,respectively.However,clinical analyses demonstrate that EBV or HPV is associated with improved response of patients,although underlying mechanism remains unclear.Here,we reported that the oncoproteins of DNA viruses,such as LMP1 of EBV and E7 of HPV,inhibit PERK activity in cancer cells via the interaction of the viral oncoproteins with PERK through a conserved motif.Inhibition of PERK led to increased level of reactive oxygen species(ROS)that promoted tumor and enhanced the efficacy of chemotherapy in vivo.Consistently,disruption of viral oncoprotein-PERK interactions attenuated tumor growth and chemotherapy in both cancer cells and tumor-bearing mouse models.Our findings uncovered a paradoxical effect of DNA tumor virus oncoproteins on tumors and highlighted that targeting PERK might be an attractive strategy for the treatment of NPC and cervical carcinoma. | Jiang He Liyu Liu Feiyu Tang You Zhou Huan Liu Can Lu Deyun Feng Hong Zhu Yitao Mao Zhi Li Lu Zhang Yuemei Duan Zhi Xiao Musheng Zeng Liang Weng Lun-Quan Sun | 2021 | Signal Transduction and Targeted Therapy2021，6，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员